Seven CAR‑T products have gained regulatory approval in China, predominantly targeting CD19 (for B‑cell leukaemia and lymphoma) and BCMA (for multiple myeloma). Each product has distinct indications. At experienced centres such as Beijing Boren Hospital, clinicians select optimal CAR‑T products tailored to each patient’s disease profile, subtype and target antigen expression.

MICM integrated diagnosis covers Morphology (M), Immunology (I), Cytogenetics (C) and Molecular biology (M), serving as the core diagnostic system for hematological malignancies. Its updated scope also incorporates two additional P modules: Pathogen detection and Pharmacogenomics (MICM-PP). Director Tong Chunrong from Beijing Boren Hospital elaborates on how this integrated system enables precise subtyping and individualized therapy for blood cancers.

Wondering why leukemia patients need genetic testing? Director Zheng Qinlong explains its vital role in precision hematology care. Genetic heterogeneity drives varied chemo responses; gene sequencing guides targeted therapy, MRD surveillance and risk stratification. Comprehensive molecular profiling avoids ineffective regimens, cuts costs and enables personalized long-term treatment plans.